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Abstract
Background: Malaria rapid diagnostic tests (RDTs) offer significant potential to improve the diagnosis of malaria, and are
playing an increasing role in malaria case management, control and elimination. Peru, along with other South American
countries, is moving to introduce malaria RDTs as components of malaria control programmes supported by the Global
Fund for AIDS, TB and malaria. The selection of the most suitable malaria RDTs is critical to the success of the programmes.
Methods: Eight of nine microscopy positive P. falciparum samples collected in Iquitos, Peru tested negative or weak positive
using HRP2-detecting RDTs. These samples were tested for the presence of pfhrp2 and pfhrp3 and their flanking genes by
PCR, as well as the presence of HRP proteins by ELISA. To investigate for geographic extent of HRP-deleted parasites and
their temporal occurrence a retrospective study was undertaken on 148 microscopy positive P. falciparum samples collected
in different areas of the Amazon region of Peru.
Findings: Eight of the nine isolates lacked the pfhrp2 and/or pfhrp3 genes and one or both flanking genes, and the absence
of HRP was confirmed by ELISA. The retrospective study showed that 61 (41%) and 103 (70%) of the 148 samples lacked the
pfhrp2 or pfhrp3 genes respectively, with 32 (21.6%) samples lacking both hrp genes.
Conclusions: This is the first documentation of P. falciparum field isolates lacking pfhrp2 and/or pfhrp3. The high frequency
and wide distribution of different parasites lacking pfhrp2 and/or pfhrp3 in widely dispersed areas in the Peruvian Amazon
implies that malaria RDTs targeting HRP2 will fail to detect a high proportion of P. falciparum in malaria-endemic areas of
Peru and should not be used. RDTs detecting parasite LDH or aldolase and quality microscopy should be use for malaria
diagnosis in this region. There is an urgent need for investigation of the abundance and geographic distribution of these
parasites in Peru and neighbouring countries.
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Introduction
Despite several decades of control efforts malaria remains a
major infectious disease, causing at least 250 million infections and
nearly 1 million deaths per year [1]. The recent significant
reductions in prevalence documented in some settings [1] through
effective use of Artemisinin-based Combination Therapy (ACT),
insecticide-treated bed nets and indoor residual spraying has given
cause for optimism and placed malaria eradication back on the
global health agenda. The ability to accurately and rapidly
diagnose malaria infection in different settings is essential to the
success of malaria control and elimination [2]. Accurate diagnosis
facilitates appropriate and prompt treatment of febrile illness,
reduces drug misuse, and minimises the risk of the development of
drug resistance.
Microscopic examination of blood smears has been the
traditional method for detecting malaria parasites. The accuracy
of microscopy largely relies on the experience and training of the
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8091microscopists and the quality of smears. Unfortunately, the quality
of microscopy varies significantly, and is often unreliable.
Importantly, good quality microscopy is particularly hard to
maintain in remote areas where malaria commonly occurs [3].
Rapid Diagnostic Tests (RDTs) for malaria have become
increasingly recognized as essential components of efforts to
improve diagnostic accuracy in areas where a large part of the
population at risk of malaria.
Malaria RDTs are lateral flow devices that detect parasite
proteins using antibodies. The tests are easy to perform and
provide rapid results (in 15 to 20 min) without the need of
electricity, expensive equipment or extensive training. RDTs have,
therefore, great potential for rapid and accurate malaria diagnosis
in most malaria-endemic areas. Today, over 50 brands of malaria
RDTs are manufactured, with over 150 individual products being
commercially available. Some detect P. falciparum only, while
others detect P. falciparum and other Plasmodium species. Most P.
falciparum-detecting RDTs target histidine rich protein 2 (HRP2).
HRP2 is an abundant protein produced by all blood stages of P.
falciparum [4], and is notable for a number of alanine and histidine
rich repeats [5].
Peru is endemic for both P. falciparum and P. vivax, with most
cases reported in the Amazon Region [6]. The rate of infection/
person/season detected by active and passive case detections in
Iquitos, the main city in the Peruvian Amazon region, was
reported as 0.13 for P. falciparum and 0.39 for P. vivax in 2003[7].
Like other malaria endemic countries, rapid and accurate malaria
diagnosis is critical for malaria control in remotes areas such as the
Amazonian region. In areas where microscopy services are not
available, diagnosis relies on blood films sent to distant centers for
evaluation, with results taking up to 3 weeks to return [8].
Presumptive treatment base on clinical symptoms is common in
these areas with a sensitivity as low as 39% [9].
Generally, HRP2-detecting RDTs show comparable sensitivity
to quality microscopy, their performance, however, has been
reported to be variable in different settings [10–18] including Peru.
One study carried out in the Peruvian Amazon during 1998 and
1999 using ParaSight F
TM commercial kit, which targets HRP2
antigen, showed 95% of sensitivity [19,20]. However, other trials
conducted in subsequent years using other RDTs that target
HRP2, including ParaScreen
TM[21] and ICT MALARIA pf/pv
(AMRAD
TM) [22], showed a sensitivity below 75%.
The performance of RDTs in the field is influenced by many
factors including quality of manufacture, storage conditions [23],
ability of the user to correctly interpret the result [24,25] and
parasite density [26]. For RDTs detecting HRP2, genetic diversity
of the Pfhrp2 gene and the protein could also affect their
performance. Indeed, the deduced amino acid sequences of
HRP2 of different isolates are highly polymorphic [27], whereby
the number and sequence of specific repeats present in the
PfHRP2 proteins varies widely. Moreover the epitopes recognised
by the Monoclonal antibodies (MAbs) specific for HRP that are
available for and used in RDTs also vary significantly between
parasites [28]. While available evidence indicates that HRP2 is the
major target detected in HRP2 RDTs, HRP3 is also secreted and
can be detected by MAbs raised against HRP2 [28]. The role of
HRP3 in performance of HRP diagnostic tests is not well defined.
Another possible factor affecting the sensitivity of HRP2-
detecting RDTs is failure of the parasite to express the antigen,
due to deletion of the gene or frame shift mutations, or alterations
in protein expression. However, to date parasite lines lacking
either or both pfhrp2 or pfhrp3 genes have only been identified
following laboratory adaptation to in vitro culture [29,30], and in
the progeny of a genetic cross [31], No reports exist in the
literature of parasites collected from human patients lacking one or
both of these genes.
During our recent characterization of pfhrp2 in parasite isolates
collected from several countries as part of the World Health
Organisation (WHO) – Foundation for Innovative New Diag-
nostics (FIND) malaria RDT evaluation program [32], we
identified a number of P. falciparum samples collected in Iquitos,
Peru, that were positive by microscopy but tested negative with
HRP2-detecting RDTs. Further characterisation of these sam-
ples revealed that they lacked either pfhrp2 or pfhrp3 or both.
Following these findings, we conducted a retrospective study to
determinetheprevalenceofpfhrp2/3 gene deletion in P. falciparum
samples collected from different malaria endemic areas in Peru.
In this paper we report the genetic characterization and the
geographic distribution of the parasites lacking pfhrp2 and/or
pfhrp3 in the Peruvian Amazon region. The implications of these
findings for various countries in South America that are moving
to introduce malaria RDTs under programmes supported by the
Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM)
are discussed.
Methods
Study Sites and Sample Collection
The samples used in this study came from two sources:
1) An active case detection survey conducted in 2007 in
communities around Iquitos, the main city in the Peruvian
Amazon area (between Nanay river, Itaya river and the left
margin of the Amazon river), Peru (Figure 1) as part of the
WHO –FIND malaria RDT evaluation program. Finger
prick blood was collected from 16 P. falciparum patients onto
filter paper and dried. Of these 9 samples met the inclusion
criteria set for the RDT QA program (HIV-hepatitis B/C
free, with no history of antimalarial chemotherapy in the last
month, and parasitemia .2000 parasites/mL). Blood spots
were transported to the Australian Army Malaria Institute for
characterisation. Aliquots of frozen blood samples were sent
to the malaria specimen bank at the Centers for Disease
Control and Prevention (CDC), Atlanta, USA for species
confirmation by 18s rRNA nested PCR and archiving, and to
the Hospital for Tropical Disease (HTD), London, UK, for
ELISA. The collection, transport and storage of the blood
samples were approved by the Human Ethics Committee
from Universidad Peruana Cayetano Heredia (UPCH
52707), Peru, while the testing of blood samples for pfhrp2
diversity was approved by the Australian Defence Human
Research Ethics Committee (ADHREC 377/05). The
remaining 7 samples were characterised together with the
retrospective samples.
2) Samples collected during previous malaria studies from
different areas of the Peruvian Amazon. A total of 159 P.
falciparum samples, collected in different studies conducted
between 2003 and 2007 by the Laboratory of Malaria at the
Institute of Tropical Medicine ‘‘Alexander von Humboldt’’-
UPCH, were available for testing. 114/159 samples came
from three different projects carried out at 11 Health post
centers in peri-urban areas around Iquitos city (Table 1). The
location and distance of these health centers to Iquitos city
are: Cardozo (3.5 Km), Mazan (38 Km), Moronacocha
(2 Km), San Juan de Miraflores (4.6 Km), 9 de octubre
(2 Km) El progreso (2.5 Km), Santa Clara de Nanay
(12 Km), Santo Tomas (16 Km), Moralillo (15 Km), Varillal
(20 Km) and Zungarococha (15 Km) (Figure 1).
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Peruvian jungle as well as from different projects (Table 1). From
this group, 12 samples were collected in Yurimaguas, located
between the Maran ˜on and Paranapura rivers (445 Km south of
Iquitos); 15 samples were from San Lorenzo, located on the shores
of the Huallaga river and nine hours from Yurimaguas by boat
(110 Km south-west from Iquitos); 7 samples came from the area
called High Jungle 2 from Jaen located 620 Km west of Iquitos
and 5 samples from Condorcanqui located 524 Km west from
Iquitos (Figure 1). The Universidad Peruana Cayetano Heredia
Ethical Committee approved the use of parasite DNA for this
study.
Other Parasite Isolates and Laboratory Lines
Genomic DNA from 10 P. falciparum field isolates collected as
part of the same WHO program: Cambodia (n=3), Myanmar
(n=2), Nigeria (n=2), Tanzania (n=2) and Madagascar (n=1),
as well as from 4 laboratory lines (3D7, 7G8, Dd2 and D10) was
used for PCR amplification of genes immediately flanking pfhrp2
and pfhrp3.
Extraction of Parasite DNA
Genomic DNA was isolated from dried blood spots on filter
paper, frozen blood or cryopreserved laboratory cultures using the
QIAblood Mini
TM, Quelex
TM-100 or Qiagen
TM kits (QIAGEN)
in accordance with the manufacturer’s instructions. Phenol-
Chloroform method was used to extract parasite DNA from
nitrocellulose strips of used RDTs [33].
Figure 1. Map of Iquitos and the Peruvian Amazon. The locations of health centers in Iquitos where the P. falciparum samples were collected
are shown in solid circles with numbers: 1, Mazan; 2, Moronacocha; 3, Cardozo; 4, San Juan de Miraflores; 5, 9 de octubre; 6, El progreso; 7, Santa Clara
de Nanay; 8, Santo Tomas; 9, Zungarococha; 10, Moralillo; 11, Varillal. The locations where samples were collected in other Peruvian Amazon areas are
shown as red dots.
doi:10.1371/journal.pone.0008091.g001
Table 1. Origin of the P. falciparum samples used.
Study area (Project) Collection Year Number of samples
Iquitos (ARTEKIN) 2003–2005 89
Iquitos (PAMAFRO) 2006 12
Iquitos (RDT QA) 2007 16*
Condorcanqui 2006–2008 8
Jaen 2005 2
San Lorenzo 2007 17
Yurimaguas 2004 15
Total P. falciparum positive samples 159
Note: All samples were diagnosed by PCR and microscopy, except for the area
of San Lorenzo where RDT (OptiMAL
TM) was used.
*Nine samples described in the Table 2 are included in this group.
doi:10.1371/journal.pone.0008091.t001
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P. falciparum infections were confirmed by PCR amplification of
4 P. falciparum specific genes:18sRNA gene, pfmsp1, pfmsp2 and pfglurp.
The P. falciparum 18sRNA gene was amplified using methods
described by Padley et al [34], modified by shortening the
extension time to 50 sec and extending the number of cycles to
45, or as described by Rubio et al [35]. The amplification pfmsp1,
pfmsp2 and pfglurp was performed using the nested primers
described elsewhere [36] for 45 cycles.
Detection of the pfhrp2 and pfhrp3 Genes by PCR
The amplification of pfhrp2 and pfhrp3 exon 2 was performed
using primers and conditions as described elsewhere [27] for 45
cycles. For the 9 samples collected in 2007, three further PCR
protocols were undertaken: to amplify across exons 1 and 2 of both
pfhrp2 and pfhrp3 and across exon 1 and the entire exon 2 of pfhrp3
using a second set of primers (Table S1).
Detection of Genes Flanking pfhrp2 and pfhrp3 by PCR
Primers (Table S1) were designed to amplify genes immediately
flanking pfhrp2: MAL7P1.230 (5.535 kb upstream) and MAL7P1.228
(6.49 kb downstream), and those immediately flanking pfhrp3:
MAL13P1.485 (4.404 kb upstream) and MAL13P1.475 (1.684 kb
downstream). The PCR conditions and expected product sizes are
described in Table S1.
DNA Sequencing
PCR products were purified by the use of spin columns (Roche),
and used in a standard dye-terminator DNA sequencing reaction
(ABI).
Detection of HRP2 Protein Using ELISA
The quantity of HRP2 protein in the 9 samples collected in
2007 was measured using the Malaria Ag CELISA kit (CELLABS
Pty, Sydney, Australia) following manufacturer’s instructions.
The protein was quantified by plotting absorbance values against
a standard curve of recombinant HRP2. Protein levels for
parasite pLDH (Standard Diagnostics, Kyonggi-do, Korea) and
aldolase (Centers for Disease Control, Atlanta, USA) were also
measured by ELISA with recombinant protein standard curves
[37].
Results
Eight of the 9 P. falciparum Samples Collected during the
2007 Survey in Iquitos Lack pfhrp2 and pfhrp3
As part of the WHO – FIND malaria RDT evaluation
program [32] we undertook characterization of pfhrp2 in 9 P.
falciparum patient samples collected in Iquitos, Peru. Eight of the
nine samples did not yield the expected PCR product using our
standard primers spanning the full length of pfhrp2 exon 2, or in
subsequent experiments using primers spanning a shorter
sequence of exon 1 and exon 2 (Table 2, Figure S1, S2),
indicating that these parasites lacked the pfhrp2 gene. In further
testing 4of these 9 samplesalso tested negativeforthepfhrp3gene
by PCR specific for exon 2 of this gene. Among the 5 samples
that had yielded the expected PCR products for exon 2 of pfhrp3
two (PE01F07 and PE01F11) failed to yield a product with
primers spanning exon 1 and exon 2, or exon 1 and full length
exon 2 of pfhrp3 (Table 2, Figure S2) indicating a truncation of
exon 1.
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Infections and Investigation for Genetic Diversity of the
Parasites
To verify the malaria parasite species and to investigate genetic
diversity in the parasites, a multiplex PCR reaction that amplifies
the 18s rRNA gene of 4 Plasmodium species commonly infecting
humans, and three polymorphic P. falciparum genes pfmsp1, pfmsp2
and pfglurp was undertaken. Results of these experiments confirmed
that all 9 samples were P. falciparum, with no evidence of
contamination or co-infection with another species (Table 2,
Figure S2). Of note, the sizes of the PCR products of the
polymorphic genes pfmsp1, pfmsp2 and pfglurp were observed to
vary, revealing 2, 2 and 4 allelic types at these loci respectively and
establishing that the isolates were not clonal in nature. The
combined three-loci-type separated the isolates into four different
haplotypes: 1) PE01F04 and PE0F06, 2) PE01F07, 3) PE01F11
and 4) PE01F15 to PE01F19 (Table 2).
Investigation of the Genetic Basis of These Deletions
To investigate for larger chromosomal deletions encompassing
the two hrp genes, PCR reactions were undertaken to amplify the
two genes flanking each of pfhrp2 and pfhrp3. The specificity of
these PCR reactions was first tested on well characterized
laboratory lines of P. falciparum. PCR products of the expected
size were amplified from two laboratory lines, 3D7 and 7G8, and
the identity of the 3D7 PCR product confirmed by DNA sequence
analysis. PCR amplification for pfhrp2 in Dd2, a laboratory line
known to lack pfhrp2 failed to amplify pfhrp2 and both flanking
genes; appropriate PCR products for pfhrp3 and both flanking
genes were amplified from this line. PCR reactions undertaken
with D10, another laboratory line known to lack pfhrp2, failed to
amplify pfhrp2 and the upstream gene, but a PCR product of the
expected size was present for the downstream gene, MAL7P1.228.
Likewise, PCR amplification of pfhrp3 and its flanking genes was
successful for D10. PCR reactions were then undertaken with 10
field isolates from different geographic areas that had yielded the
expected pfhrp2 and pfhrp3 products, and also yielded products of
the expected size for the four genes flanking both pfhrp2 and pfhrp3
(Table S2).
When the Peruvian isolate PE01F04, the only isolate positive for
pfhrp2 in this subset, was subject to PCR for the genes flanking
pfhrp2, it yielded products for both flanking genes as was observed
with 3D7 and 7G8. PCR reactions undertaken with the remaining
8 Peruvian samples, which were negative for pfhrp2, resulted in
amplification of the expected product for the downstream gene but
failed to amplify the gene upstream of pfhrp2, in a pattern
resembling that observed with D10. Isolates PE01F04, PE01F06
and PE01F15 that had yielded phfhp3 PCR products were also
PCR-positive for both genes flanking pfhrp3. PE01F07 and
PE01F11, isolates where evidence had indicated that may have
truncated exon 1 were PCR positive for the upstream gene but
negative for the downstream gene. The four samples that had
failed to yield a PCR product for pfhrp3 were all PCR-negative for
the upstream flanking gene, and 3 of the 4 samples were also
negative for the downstream gene (Table 2, Figure S2).
Verification that These Parasites Do Not Produce HRP
Protein
To investigate whether these parasites lacked histidine rich
protein all 9 samples were screened for HRP2 protein levels by a
HRP antigen capture ELISA. Only one of the 9 samples
(PE01F04) had detectable histidine rich protein 2, giving an
estimated 235 ng/mL protein (Table 2). In contrast, all 9 samples
had measurable levels of pLDH and aldolase. When tested on 3
different commercially available HRP2-detecting RDTs, PE01F04
again was the only sample test positive with all 3 RDTs. Two
samples lacking pfhrp2 but having intact pfhrp3 (PE01F06 and
PE01F15) tested weakly positive on the ICT combo kit (Cape
Town, South Africa). PE01F06 tested weakly positive but
PE01F15 was negative with 2 other RDT brands (CareStart
Malaria HRP2 and CareStart Malaria Combo. AccessBio,
Monmouth, NJ, USA). The remaining 5 samples lacking both
phfrp2 and pfhrp3 were negative on all 3 different RDTs.
A High Proportion of Retrospectively Collected Samples
from the Amazon Region of Peru Lack pfhrp2 and pfhrp3
Genes
We then undertook study of the presence of hrp-deleted parasites
from other areas of Peru. PCR amplifications of the 18SrDNA gene
and pfglurp was performed for 159 samples that had been collected
in previous studies, of which 148 were positive for both markers
confirming P. falciparum infection and indicating a good quality of
DNA. The size of the PCR product for pfglurp varied ranging from
550 to 900 bp, indicating a total of 6 genotypes (Table 3). These
148 samples were then tested for the presence of pfhrp2 and pfhrp3
by PCR.
Of 114 samples collected from peri-urban areas of Iquitos, PCR
for the pfhrp2 and the pfhrp3 genes failed in 36% and 67% of the
samples respectively (Table 4), despite being positive for 18sRNA
and pfglurp. The proportion of samples failing to amplify both
pfhrp2 and pfhrp3 was 18.4% (21/114), while the proportion of
samples positive for both genes was only 15.78% (18/114).
pfhrp2 and pfhrp3 Deleted Parasites are Widely
Distributed in the Peruvian Amazon
Parasites lacking pfhrp2 and pfhrp3 were also identified in other
areas in the Peruvian jungle. The proportion of pfhrp2 and pfhrp3
positive and negative in samples collected in Condorcanqui, San
Lorenzo, Yurimaguas and Jaen is shown in table 4. The
proportion varied between parasites collected in different areas.
While the number of samples collected in these areas was small,
overall a high proportion of parasites negative for pfhrp2 and pfhrp3
was observed in these areas and was comparable to levels observed
around Iquitos. When all areas are combined, we observed that a
total of 41% and 70% of the samples were negative to pfhrp2 and
pfhrp3, respectively (Table 4). The percentage of samples that were
negative for both pfhrp2 and pfhrp3 was 21.6% (32/148), while the
percentage of samples that were positives for both pfhrp2 and pfhrp3
was 13.5% (20/148).
Table 3. pfglurp allelic type detected in the retrospective
samples.
Genotype Size in base pairs Number of samples
A 550–600 27
B 600–650 25
C 650–700 19
D 700–750 36
E 750–800 29
F 800–900 12
Total samples 148
doi:10.1371/journal.pone.0008091.t003
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In order to rule out the possibility that failure to PCR amplify
the pfhrp2/3 genes was due to possible polymorphisms at the
primer binding sites, an additional PCR reaction was undertaken
for samples that were negative for either genes using the same
primers with lower annealing temperatures (down to 42uC). All
samples and the negative controls remained negative, while the
positive control (NF54) was positive, suggesting that no small
mismatches occurred at the primer sites (Figure S3).
Discussion
Laboratory lines of P. falciparum that lack pfhrp2 or pfhrp3 or both
genes have been reported following adaptation to and long term
growth under in vitro culture conditions [29–31]. However, this is
the first report of clinical isolates of parasites taken directly from
infected human subjects in endemic areas lacking these genes. As
part of the WHO-FIND malaria RDT evaluation program we
have examined pfhrp2 sequence variation of over 500 clinical
parasite samples collected from many different malaria endemic
areas in Africa, South East Asia, West Pacific and South America
([27] and Baker et al unpublished) and have not encountered P.
falciparum samples lacking pfhrp2 and/or pfhrp3 elsewhere. In Peru,
we identified, for the first time, not only parasites from clinical
patients lacking these hrp genes but also a wide spread pattern of
parasites lacking these genes in the Peruvian Amazon with an
overall frequency of 41% and 70% of parasites without pfhrp2 and
pfhrp3, respectively and 21.6% for double deletions.
pfhrp2 and/or pfhrp3 PCR Negative Samples Lack These
Genes Due to Chromosomal Deletions
A plausible hypothesis for the negative PCR results for pfhrp2
and/or pfhrp3 is that these parasites lack these genes as a
consequence of chromosomal deletion. A commonly used method
for characterizing genetic rearrangements and deletions is a
genomic hybridization where parasite genomic DNA or parasite
chromosomes are hybridised with the target gene (generally by
Southern Blot), in this case, pfhrp2 or pfhrp3. Since we only had
blood spots on filter paper and small aliquots of frozen whole
blood, there was insufficient parasite genomic DNA to use this
method. Instead, we performed a number of independent PCR
experiments to characterise the samples to obtain supporting
evidence that the parasites actually lack these genes. These
experiments also ensured that the negative PCR reactions for
pfhrp2 and pfhrp3 were not due to poor quality or insufficient
parasite DNA. To rule out the possibility of sequence polymor-
phism at primer binding sites, further PCR experiments were
undertaken using alternative primers designed to anneal at highly
conserved sequence stretches in both pfhrp2 and pfhrp3. All isolates
that were PCR negative using the exon 2 pfhrp2 and pfhrp3 primers
were also PCR negative using these latter primers.
Deletions of pfhrp2 and pfhrp3 previously reported in laboratory
lines have all been shown to result from chromosomal deletions,
where a large fragment of a chromosome usually containing
several genes is deleted [29–31]. Further evidence that 8 of the 9
and 6 out 9 Iquitos parasites lack pfhrp2 or both pfhrp2 and pfhrp3,
respectively, is provided by the observation that the negative PCR
reactions for the flanking genes were consistent with those for
pfhrp2 and pfhrp3. Taken together, the results suggest that a
fragment on chromosome 7 that contains pfhrp2 and its immediate
upstream gene (MAL7P1.230) encoding a hypothetical protein has
been deleted in these parasites. In all 8 isolates negative for pfhrp2,
the gene immediately downstream from pfhrp2 encoding HSP70 is
preserved. On chromosome 13, PCR reactions for both pfhrp3 and
the genes immediately upstream (MAL13P1.485), and in most
cases for the downstream gene (MAL13P1.475) were negative for
4 of the 9 samples, indicating a chromosomal deletion. This
finding is supported by independent data showing that chromo-
somal deletions in both the region on chromosome 7 where pfhrp2
is located, and the region on chromosome 13 where pfhrp3 is
located, are possible and have been observed in some laboratory
parasite lines [38].
Parasite Lack pfhrp2 and/or pfhrp3 Do Not Express HRP2
Protein and Are Not Detectable by HRP2 Detecting RDTs
Most importantly from the standpoint of diagnostic assay
performance, the final evidence of gene deletion or inactivation,
came from the assay for histidine-rich protein by ELISA where
results show that with the exception of one parasite isolate none
have detectable histidine rich protein 2, though all isolates have
detectable pLDH. The single isolate in this subset of samples in
which histidine-rich protein could be detected was positive for
both pfhrp2 and pfhrp3. When tested using HRP2-detecting RDTs,
parasites having double gene deletions all tested negative on
different HRP2-detecting RDTs demonstrating the lack of
antigens in these parasites. Parasites having deleted only phfrp2
but not pfhrp3 were detectable by some RDTs but not others
resembling the ELISA results due, most likely, to different
antibodies used in different RDTs or ELISA test which recognise
different epitopes that may or may not be shared between pfhrp2
and pfhrp3 [28].
A Large Proportion of P. falciparum Parasites in Peruvian
Amazon Lack pfhrp2 and pfhrp3
Evidence for a widespread distribution of HRP-deleted parasites
across the Peruvian Amazon comes from our observation that a
Table 4. Proportion of P. falciparum isolates positive or negative for pfhrp2/3 genes in different areas of the Peruvian Amazon.
Area No. pfhrp2 – PCR pfhrp3 – PCR pfhrp2/pfhrp3
Pos (%) Neg (%) Pos (%) Neg (%) double positive (%) double negative (%)
Iquitos 114 73 (64) 41 (36) 35 (31) 79 (69) 18 (15.8) 21 (18.4)
Condorcanqui 5 0 (0) 5 (100) 4 (80) 1 (20) 0 (0) 1 (20)
San Lorenzo 15 8 (53) 7 (47) 2 (13) 13 (87) 1 (6.7) 6 (40)
Yurimaguas 12 6 (50) 6 (50) 2 (17) 10 (83) 1 (8.3) 4 (33.3)
Jae ´n 2 0 (0) 2 (100) 2 (100) 0 (0) 0 (0) 0 (0)
Combined 148 87 (59) 61 (41) 45 (30) 103 (70) 20 (13.5) 32 (21.6)
doi:10.1371/journal.pone.0008091.t004
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observed in other areas from the Peruvian jungle between 110 and
620 kilometres from Iquitos (Condorcanqui, San Lorenzo,
Yurimaguas and Jaen) and collected over a period of 4 years.
These findings indicate that the hrp-negative parasites are not
restricted to a specific area, but are distributed in much of the
malaria endemic areas in Peru, and raises the possibility that such
parasites may be present in neigbouring countries with identical
patterns of malaria and sharing the same river system for
transport.
The Absence of HRP2 and HRP3 Likely Explains the Poor
Performance of Some HRP2-Detecting RDTs Previously
Reported in the Peruvian Amazon
The previously reported sensitivity for these tests ranged from
70% [21] to 65% (MALARIA pf/pv (AMRAD
TM)) [22], consistent
with our findings, while pfLDH-detecting RDTs (OptiMAL) have
shown higher sensitivity in the Peruvian Amazon [39–42].
ParaSight F (Becton-Dickensen, USA) was trialed in Iquitos for
several years before 2000 showing good sensitivity in detecting P.
falciparum infections [19,20]. It is possible that at that time,
parasites lacking pfhrp2 were not present in high proportions to
affect the performance of this test. Therefore, the widespread of
parasites lacking pfhrp2 gene may be a relatively recent event.
Parasite Evolution
The evolutionary process that produced these parasites is
unknown but intriguing. It is notable that the proportion of
parasites lacking pfhpr3 is higher than those lacking pfhrp2 in
samples collected from almost all locations, while the proportion of
parasites lacking both genes is 21.6%. This suggests that parasites
lacking pfhrp3 may have been present in Peru longer than those
lacking pfhrp2. It is possible that parasites lacking pfhrp3 had
undergone a genetic cross with parasites lacking pfhrp2 and
produced progeny lacking both genes. As four different pfmsp1/
pfmsp2/pfglurp haplotypes were observed in the subset of 9 isolates
lacing pfhrp2, chromosomal deletions on chromosome 7 may have
occurred frequently in the area. A similar genetic cross event and
outcome has been reported in a laboratory cross where Dd2 (pfhrp2
negative) and HB3 (pfhrp3 negative) were crossed. While most
progeny inherited either a pfhrp2 or a pfhrp3 deletion, one progeny
(3BD5) lacked both pfhrp2 and pfhrp3 according to genetic linkage
analysis [31].
While the function(s) of pfhrp2 and pfhrp3 is unclear, they do not
appear to be essential for in vitro growth because progeny lacking
either gene or both pfhrp2 and pfhrp3 remain viable in vitro, with
exhibition of a rapid growth phenotype. This observation of wild-
type parasites lacking both pfhrp2 and pfhrp3 from patients in Peru
indicate that these parasites are viable in vivo. Further study of
parasite virulence and fitness in these deletion mutants would be
of interest, but they are obviously capable of transmission and of
causing disease as all cases were symptomatic. Certainly, the
mechanism of selection that has driven these parasite genotypes to
be common in this Peruvian population of P. falciparum remains to
be determined.
HRP2-Detecting RDTs Are Not Reliable in Peru
The most important implication of this finding is that, in most
malaria endemic areas of Peru, diagnosis of the malaria due to P.
falciparum, the species responsible for almost all malaria mortality
and much of the morbidity, would commonly fail if HRP2-
detecting RDTs are used. This raises a serious question
concerning on the value of the use of HRP2-detecting RDTs in
Peru. Because P. falciparum is endemic in a great area of the
Peruvian Amazon with 98% of the falciparum malaria cases in Peru
occur in this area [6], any malaria RDT used here must detect P.
falciparum with high sensitivity. The high proportion of samples in
which pfhrp2 could not be amplified (41%) and high proportion of
samples lacked both pfhrp2 and pfhrp3 (21.6%) in this study, which
were collected from different areas and at different time points,
clearly demonstrate that HRP2-detecting RDTs have limited
reliability for detecting P. falciparum in Peru. RDTs targeting other
antigens (pLDH and aldolase) and quality microscopy should be
used for malaria diagnosis.
As Peru borders on several countries that share the Amazon
River basin and where malaria transmission occurs without
respect for national borders, it is unlikely that parasites lacking
pfhrp2 and pfhrp3 are confined to Peru. It is therefore important
that investigations be performed in other areas in South America
urgently where P. falciparum is endemic to determine the presence
and geographical spread of parasites lacking the pfhrp2 and pfhrp3
genes before the large scale implementation of malaria RDTs in
this area. Investigations should also be carried out to monitor the
presence and spread of parasites with gene deletions in areas
outside of South America to ensure the best performance of
malaria RDTs globally.
Supporting Information
Figure S1 Schematic illustration of pfhrp2 and pfhrp3 gene
structures and primer binding sites. Filled arrows represent
primers that amplify the full length exon 2; open arrows
representing primers amplify across exon 1 and exon 2.
Found at: doi:10.1371/journal.pone.0008091.s001 (0.05 MB TIF)
Figure S2 PCR products visualised on agarose gels. Panels a) to
l) shows the PCR results for: a) pfhrp2 exon 2, b) pfhrp2 exon 1-
exon 2, c) pfhrp3 exon 2, d) pfhrp3 exon 1-exon 2, e) 18s rRNA, f)
pfglurp, g) pfmsp1, h) pfmsp2, i) MAL7P1.228, j) MAL7P1.230, k)
MAL13P1.475, l) MAL13P1.480. Numbers 1 to 12 represent lanes
on each gel: 1: Marker; 2: PE01 F04; 3: PE01 F06; 4: PE01 F07; 5:
PE01 F11; 6: PE01 F15; 7: PE01 F16; 8: PE01 F17; 9: PE01 F18;
10: PE01 F19; 11: 3D7; 12: No DNA
Found at: doi:10.1371/journal.pone.0008091.s002 (0.51 MB TIF)
Figure S3 Temperature Gradient for PCR. A: pfhrp2 positive
samples. Lane 1: 100 pb plus Molecular marker (MM) - RocheTM;
Lane 2: 42.0uC; Lane 3: 43.0uC; Lane 4: 45.0uC; Lane 5: 47.0uC;
Lane 6: 48.0uC; Lane 7: 50.0uC; Lane 8: NF54; Lane 9: Negative
control (NC) to 50.0uC. B: pfhrp2 negative samples. Lane 1: MM;
Lane 2: 50.0uC; Lane 3: 48uC; Lane 4: 47.0uC; Lane 5: 45.0uC;
Lane 6: 44.0uC; Lane 7: 43.0uC; Lane 8: 42.0uC; Lane 9: NF54
(50.0uC); Lane 10: NC. C: pfhrp3 positive samples. Lane 1: MM;
Lane 2: 50.0uC; Lane 3: 48.0uC; Lane 4: 47.0uC; Lane 5: 45.0uC;
Lane 6: 44.0uC; Lane 7: 43.0uC; Lane 8: 42.0uC; Lane 9: NC. D:
pfhrp3 negative samples. Lane 1: MM; Lane 2: 50.0uC; Lane 3:
48.0uC; Lane 4: 47.0uC; Lane 5: 45.0uC; Lane 6: 44.0uC; Lane 7:
43.0uC; Lane8: 42.0uC; Lane 9: 41.0uC; Lane10: 40.0uC; Lane 11:
NC.
Found at: doi:10.1371/journal.pone.0008091.s003 (0.29 MB TIF)
Table S1 Primer sequences, PCR conditions and expected
product sizes
Found at: doi:10.1371/journal.pone.0008091.s004 (0.01 MB
DOC)
Table S2 Amplification of pfhrp2, pfhrp3 and their immediate
flanking genes in laboratory lines and field isolates.
Found at: doi:10.1371/journal.pone.0008091.s005 (0.01 MB
DOC)
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